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Abstract 
Periprosthetic osteolysis is a serious complication of total hip replacement in the medium to long-term. 
Although often asymptomatic, osteolysis can lead to prosthesis loosening and periprosthetic fracture. 
These complications cause significant morbidity and require complex revision surgery. Here, we 
review advances in our understanding of the cell and tissue response to particles produced by wear of 
the articular and non-articular surfaces of prostheses. We discuss the molecular and cellular regulators 
of osteoclast formation and bone resorptive activity, a better understanding of which may lead to 
pharmacological treatments for periprosthetic osteolysis. We describe the development of imaging 
techniques for the detection and measurement of osteolysis around total hip replacement prostheses, 
which enable improved clinical management of patients, provide a means of evaluating outcomes of 
non-surgical treatments for periprosthetic osteolysis, and assist in pre-operative planning for revision 
surgery. Finally, there have been advances in the materials used for bearing surfaces to minimise wear, 




The problem of periprosthetic osteolysis 
Loosening of hip replacement prostheses due to loss of adjacent bone, known as peri-prosthetic 
osteolysis, is the most common reason for revision of total hip replacements in the medium to long-
term
1-3
. Non-linear periprosthetic osteolysis is characterised by localised and often ballooning lesions 
in bone adjacent to prostheses and is often first noted around stable prostheses before the bone loss 
leads to loosening
4
. Even when this type of osteolysis is progressive and results in major bone loss, 
patients may remain asymptomatic until the bone fails to support the prosthetic implant, at which time 
major revision surgery is required.   
 
Fluid pressure and wear particles at the bone prosthesis interface cause osteolysis 
The mechanism of periprosthetic osteolysis is likely to be multifactorial. While factors such as 
prosthesis design, surgical technique and quality of fixation are known to be important for early 
loosening of prostheses, loosening of prostheses due to osteolysis in the medium to long term is related 
more to prosthesis materials and the type and volume of wear particles generated, and the resultant 
tissue reaction. Osteolysis around long-term implanted prostheses has been attributed to both the tissue 
response to wear particles derived from both the articular and non-articular interfaces of prostheses and 
to fluid movement and pressure at the prosthesis-bone interface.  
 
Histological examination of tissue retrieved from the joint capsule and from the prosthesis-bone 
interface around hip replacements revised for loosening and osteolysis revealed large numbers of 
prosthesis-derived particles and an inflammatory response. This was characterised by the presence of 
macrophages, multinucleated foreign body giant cells containing engulfed particles, lymphocytes, 
fibroblasts and osteoclasts on bone surfaces.
5,6
 We reported a direct association between wear particles 
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and osteoclastic bone resorption in 1988
7
. In an in vivo rat model of joint replacement, which allowed 
movement of fluid and wear particles to the periprosthetic bone, the presence of wear particles led to 
the formation of a connective tissue layer of variable thickness at the prosthesis-bone interface and 
osteolytic lesions.  
 
Animal studies and studies examining retrieved interface tissue have determined that a number of 
particle-associated factors influence the extent and type of chronic inflammatory tissue response and 
the extent of osteolysis
8-14
. These include the chemical composition of the prosthesis, the size, shape 
and surface area of the particles generated, as well as the rate of production and thus concentration of 
particles present. While wear resulting in excessive numbers of particles being shed from any of the 
components of a hip replacement will initiate an inflammatory response leading to osteolysis, 
irrespective of the material used, the large numbers of wear particles generated by wear of the 
polyethylene liner are the most common cause
15-17
. Wear of metal components resulting in the 
generation of metal particles and metal ions is usually related to poor prosthesis design or occurs as a 
result of wear through of the polyethylene liner leading to metal on metal wear. 
 
Identification of bone resorbing mediators  
Phagocytosis of these wear particles by macrophages is now known to initiate a cascade of events that 
leads to osteolysis and prosthesis loosening. The particle-stimulated macrophages express a number of 
inflammatory mediators, including cytokines (IL-1β, TNFα, IL-6, IL-8 and IL-11), colony stimulating 
factors (M-CSF and GM-CSF), prostaglandins (PGE2), matrix metalloproteinases and chemokines
18-23
. 
The release of these mediators stimulates the recruitment and activity of more macrophages and other 
cells such as fibroblasts to the prosthesis-bone interface. Mononuclear precursors of osteoclasts are 
known to be present within the macrophage infiltrate, which are capable of differentiating into 





In addition to these inflammatory mediators, we have shown that an accumulation of wear particles is 
also frequently associated with a marked increase in expression of receptor activator NF-κB ligand 
(RANKL) and its receptor, RANK
27,28
. It is well established that the activated RANKL/RANK ligand-
receptor complex is central to the differentiation and activity of osteoclasts, and therefore bone 
resorption
29-31
. The expression and activity of RANKL is known to be induced by a number of pro-





Immunohistochemical and in situ hybridisation studies of periprosthetic tissue from sites adjacent to 
osteolytic lesions have revealed that macrophages, multinucleated giant cells and, to a lesser extent, 
fibroblasts express high levels of RANK, RANKL and TNFα26,28,35. Our studies have found strong 
correlations between osteolytic lesion size, the concentration of polyethylene particles, and RANK, 
RANKL and TNFα expression28. We have investigated the direct effect of prosthesis-derived 
polyethylene particles on differentiating human osteoblasts, using a 3D collagen gel culture system
36
. 
This system provides the necessary architecture and microenvironment to allow normal human 
osteoblastic cells to undergo differentiation into a mature osteocyte-like phenotype over a 21 to 28 day 
culture period, indicated by increased mRNA expression of osteocyte markers such as E11, DMP1 and 
SOST, and adoption of a stellate morphology
36
. In the presence of polyethylene particles, the 
osteocyte-like cells increase their expression of mRNA species that are associated with the promotion 
of osteoclast formation and activity (RANKL, IL-8 and M-CSF) and a concomitantly decreased 
expression of the osteoclast antagonist, osteoprotegerin. Qualitatively similar results were found after 
exposure of the mouse MLO-Y4 osteocyte-like cell line to polyethylene particles. We have also shown 
that inflammatory mediators can upregulate the expression, by human osteocyte-like cells, of the 
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negative regulator of bone formation, sclerostin
37
. These results suggested that polyethylene particles 
might directly or indirectly influence the behaviour in bone of osteocytes, now increasingly recognised 
as directing both bone formation and bone resorption
38
. In support of this, we have shown expansion of 
the osteocyte lacunae adjacent to polyethylene particles in the mouse calvarial osteolysis model (Atkins 
et al., unpublished). Direct effects were also found on osteoclast differentiation and activity after 
exposure to polyethylene particles in the collagen gel model. Osteoclasts generated by treatment with 
RANKL had increased resorptive activity if they were concurrently exposed to polyethylene particles, 
as well as increased expression of the immunoreceptor tyrosine-based activation motif (ITAM)-related 
molecules OSCAR, FcRγ, TREM2 and DAP12, which are important for osteoclast formation39. 
 
These findings from in vitro and in vivo studies and studies examining interface tissue directly link 
polyethylene particles to key mediators of osteoclast formation and bone resorption activity in 
periprosthetic osteolysis and suggest that treatment with inhibitors of these mediators may be useful in 
preventing or delaying periprosthetic osteolysis.  
 
Non-surgical treatment of osteolysis 
A better understanding of the biology of periprosthetic osteolysis may lead to pharmacological 
approaches to its treatment when prostheses remain well fixed in situ. Studies with anti-resorptive 
agents in animal models have shown promise
40,41
 and a small number of studies have been carried out 
in patients with periprosthetic osteolysis using anti-resorptive drugs, including bisphosphonates and the 
anti-TNFα inhibitor, Etanercept42,43. Gene therapy has also been proposed for the treatment of 
periprosthetic osteolysis
44-46
. However, although agents such as bisphosphonates and a human 
monoclonal antibody to RANKL, denosumab, have shown efficacy in reducing the systemic bone loss 
of osteoporosis
47
, an evidence base for using these agents clinically in established periprosthetic 
osteolysis is so far lacking. To evaluate the role of these and other potential treatments for 
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periprosthetic osteolysis, treatment protocols will need to be based on the severity of the osteolysis and 
its rate of progression and, importantly, accurate measurement of osteolysis will be required for such 
treatments to be properly evaluated. 
 
Detection, assessment, measurement and monitoring of osteolysis 
It is now generally accepted that plain radiography is not sufficiently sensitive for the reliable detection 
of the presence or extent of periprosthetic osteolysis
48-50
. High resolution multi-slice or helical CT with 
metal artifact reduction protocols have been developed to provide a sensitive and accurate measure of 
the volume of osteolytic lesions close to metal prostheses
49-54
. We and others have evaluated the 
accuracy of CT to detect osteolytic lesions
49,50,54
, and have used it to identify patient and prosthesis-




Our clinical CT studies to date have focussed on periacetabular osteolysis around cementless acetabular 
components in the medium to long term post-implantation
56-58
. Periacetabular osteolysis is the major 
long-term complication of these prostheses, and is often seen in the presence of well-fixed components. 
The aim of our studies has been to understand the natural history of these lesions and the factors that 
promote their formation and progression. Specifically, we have sought to obtain accurate data on the 
size and progression of periprosthetic lesions in patients suspected of having osteolysis, so as to 
improve patient management and to assist in planning for revision surgery. 
 
The progression of periacetabular osteolysis over prolonged periods of up to nine years was monitored 
using CT, in a cohort of patients with cementless acetabular components who were suspected of having 
periacetabular osteolysis. We found that patients either developed low volumes of osteolytic lesions 
that were relatively quiescent, even after long periods of implantation, or patients had extensive, 
progressive periacetabular osteolytic lesions after a similar post-operative period
56,58
. The latter group 
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is therefore likely to be at higher risk of acetabular component loosening, component migration and 
acute periprosthetic bone fracture. Several factors were found to be good predictors of progression of 
osteolysis, particularly the volume of the osteolytic lesions at initial CT and patient activity
58
. The 
strongest predictor of progression was obtained by combining these two risk factors. Thus, patients 
with a high volume of osteolysis at the initial CT and those who were most active had the largest 
increases in osteolytic lesion size over the monitoring period. These data have significant implications 
for monitoring patients over time and will potentially identify which patients might best be targeted for 
novel treatments or early surgical intervention.  
 
Surgical treatment of osteolysis 
The decision to revise patients with asymptomatic periacetabular osteolysis adjacent to 
radiographically stable acetabular components is complex. Important factors to consider include 
impending wear-through of the polyethylene liner or large, rapidly progressing osteolytic lesions, 
particularly if fixation of the cup is threatened
59,60
, as well as life expectancy and co-morbidities of the 
patient, and prosthesis type
2,3,60
. The loss of bone due to periprosthetic osteolysis can compromise the 
outcome of revision joint replacement and multiple revisions on the same joint are not uncommon, with 
a reduction in average prosthesis survival for each subsequent revision procedure
61
. When revision 
surgery is indicated in the presence of significant periprosthetic osteolysis, the planning of that surgery 




With the introduction of modular hip components, liner exchange surgery, without removal of the 
metal shell, has emerged as a surgical treatment option in certain circumstances in the presence of well-
fixed acetabular components. During this surgery, if osteolytic lesions can be accessed through empty 
screw holes in the metal shell or by cortical ‘windows’, debridement and bone grafting of the lesions 
 8 
can be undertaken to replace bone lost in the osteolytic process. The alternative surgical treatment 
option is revision of the entire acetabular component. However, removal of a well-fixed acetabular 
component could potentially result in significant loss of acetabular bone stock, thereby increasing the 
risk of insufficient bone ingrowth and hence subsequent loosening of the new acetabular component.  
 
Using serial CT scans, it is now possible to monitor and subsequently compare the progression of 
individual osteolytic lesions prior to and after liner exchange surgery, thereby enabling assessment of 
the effect on osteolytic lesion progression of removing the source of polyethylene particles as well as 
being able to monitor the integration of the bone graft
63
. An example of longitudinal monitoring of 
periacetabular osteolytic lesions pre- and post-liner exchange surgery/grafting using serial CT scans is 
shown in Figure 1. Despite this patient maintaining his activity levels following liner exchange, this 
surgery appeared to halt the progression in size of the osteolytic lesions.   
 
Advances in orthopaedic materials 
The orthopaedic device industry continues to develop materials with purportedly improved wear 
properties.  Polyethylene, the polymer most commonly used in articulations, has undergone evolution 
over the five decades of its use. Most recently, the ongoing problem of wear of the conventional ultra 
high molecular weight polyethylene in bearing surfaces prompted the development of highly cross-
linked polyethylenes. Increasing the cross-linking of the polymer has been shown in vitro to result in 
significantly lower polyethylene wear rates in hip simulator studies
64-66
. Over the last decade, highly 
cross-linked polyethylenes have largely replaced conventional polyethylene as the polyethylene of 
choice in acetabular liners, and their lower wear has been confirmed clinically using sensitive 
radiographic in vivo measures of wear
67-69
. Polyethylene cross-linking is achieved with the use of 5 to 
10 Mrad of gamma or electron-beam irradiation. Early cross-linked polyethylenes were manufactured 
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using 5 Mrad irradiation and were known as moderately cross-linked polyethylenes. Currently, most 
polyethylenes are highly cross-linked, achieved through the use of 9.5-10 Mrad irradiation.   
 
The decreased wear rate has, however, been identified as a trade-off against reduced mechanical 
properties of the highly cross-linked polyethylenes, compared to the previous conventional 
polyethylenes
70,71
. A small number of cases of rim cracking and rim fractures have been reported
72,73
. 
Most of these appear related to excess loading on unsupported thinner polyethylene in malpositioned 
acetabular components. This has led to the development of a new generation of polyethylenes, namely 
highly cross-linked polyethylenes stabilised with vitamin E to reduce oxidation which appear to 
provide improved mechanical properties in vitro
74,75
. Long term results of these materials are not yet 
available.  
 
Laboratory studies have suggested that wear particles generated from highly cross-linked polyethylene 
may cause an increased biological response, which may in turn lead to osteolysis despite a low wear 
rate
76-78
. Specifically, highly cross-linked polyethylene particles were found to be significantly more 
inflammatory than conventional polyethylene particles, based on the relative cytokine release from 
macrophages in vitro
77,78
. Furthermore, although laboratory wear of highly cross-linked polyethylene 
particles produces fewer particles overall, the relative percentage of small wear particles, namely those 





Importantly, there is little clinical evidence to date that the reduction in wear of highly cross-linked 
polyethylene translates to a decrease in periprosthetic osteolysis. A number of studies of highly cross-
linked polyethylenes have reported a low incidence of osteolysis on plain radiographs
67-69
, but the 
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sensitivity of plain radiographs in detecting osteolytic lesions is poor. In two small studies using CT, 
the reported incidence of osteolysis at 5-6 years ranged from 2% to 8% in patients with cross-linked 
polyethylene liners
79,80
. Using CT, we have also identified a number of cases of osteolytic lesions 
exceeding 1cm
3
 at seven years following total hip replacement with highly cross-linked polyethylene 
liners (Howie et al. unpublished). The concern arising from these studies is that osteolysis was detected 
in the absence of significant wear of the polyethylene liner. Reduced wear of cross-linked polyethylene 
may therefore not correspond to a similar level of reduction in the incidence of osteolysis.  
 
Concluding remarks 
An integrated approach to understanding periprosthetic osteolysis has identified particles resulting from 
wear of the prosthetic materials, especially polyethylene, as essential drivers of this process. 
Knowledge of the cellular and molecular mechanisms for periprosthetic osteolysis may lead to non-
surgical approaches to inhibiting bone loss and thereby prolonging the useful life of prostheses. 
Improved imaging of osteolytic lesions through the use of CT is providing new insights into the natural 
history of periprosthetic osteolysis and more informative ways to monitor osteolytic lesions in patients. 
Imaging will also assist not only in identifying patients who may benefit from drug therapy, but also in 
determining clinically relevant outcomes. Finally, although it is now recognised that cross-linking 
reduces polyethylene wear, more clinical studies are needed to determine if cross-linking will also 
reduce the incidence of periprosthetic osteolysis and hence significantly improve the long-term 
outcomes of total hip repacement. 
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Fig 1A-D. A. Longitudinal monitoring of periacetabular osteolytic lesions pre- and post-liner exchange 
surgery using serial CT scans. Total osteolytic lesion volumes are shown for one patient prior to   
(  ) and following ( ) liner exchange surgery. B-C. Selected sagittal images from the CT 
scans of this patient, which show an osteolytic lesion adjacent to the acetabular component (arrows) 
increasing in size from 20.1 cm
3
 (B) to 29.7 cm
3
 (C) three years later. D. Sagittal CT image of the same 
osteolytic lesion three years after liner exchange surgery showing fill of the lesion with bone graft 
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